References
- Valdivieso M, Kujawa AM, Jones T, et al. Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci. 2012;9(2):163–173.
- Fidler MM, Gupta S, Soerjomataram I, et al. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18(12):1579–1589.
- Johnson JA, Tough S, Wilson RD. Society of obstetricians and gynaecologists of Canada. Delayed child-bearing. J Obstet Gynaecol Can. 2012;34(1):80–93.
- Condorelli M, Lambertini M, Del Mastro L, et al., Fertility, sexuality and cancer in young adult women. Curr Opin Oncol. 2019;31(4): 259–267.
- Lambertini M, Anserini P, Fontana V, et al., The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. BMC Cancer. 2017;17(1): 346.
- Lambertini M, Peccatori FA, Demeestere I, et al. ESMO guidelines committee. Electronic address: [email protected]. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1664–1678.
- Dalmartello M, Negri E, La Vecchia C, et al. Frequency of pregnancy-associated cancer: a systematic review of population-based studies. Cancers (Basel). 2020;12(6):1356. 26.
- Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling (Federal Register/Vol. 73, No. 104/ 2008 May 29). https://www.govinfo.gov/content/pkg/FR-2008-05-29/pdf/E8-11806.pdf
- Lorenzi E, Simonelli M, Santoro A. Infertility risk and teratogenicity of molecularly targeted anticancer therapy: a challenging issue. Crit Rev Oncol Hematol. 2016;107:1–13.
- Carlsson IB, Laitinen MP, Scott JE, et al. Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture. Reproduction. 2006;131(4):641–649.
- Mauduit C, Hamamah S, Benahmed M. Stem cell factor/c-kit system in spermatogenesis. Hum Reprod Update. 1999;5(5):535–545.
- Nilsson EE, Detzel C, Skinner MK. Platelet-derived growth factor modulates the primordial to primary follicle transition. Reproduction. 2006;131(6):1007–1015.
- Mariani S, Basciani S, Arizzi M, et al. PDGF and the testis. Trends Endocrinol Metab. 2002;13(1):11–17.
- Hutt KJ, McLaughlin EA, Holland MK. Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod. 2006;12(2):61–69.
- Nurmio M, Toppari J, Zaman F, et al. Inhibition of tyrosine kinases PEDGFR and C-kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl.. 2007;30(4):366–376.
- Nurmio M, Kallio J, Toppari J, et al. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. Reprod Toxicol.. 2008;25(4):442–446.
- Basciani S, De Luca G, Dolci S, et al. Platelet-derived growth factor receptor beta-subtype regulates proliferation and migration of gonocytes. Endocrinology. 2008;149(12):6226–6235.
- Schultheis B, Nijmeijer BA, Yin H, et al. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res. 2012;36(3):271–274.
- Hochhaus A, Saussele S, Rosti G, et al. ESMO guidelines committee. chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(28):iv41–iv51.
- Demetri GD, von Mehren M, Antonescu CR, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2(0 2)):S1–41.
- Imatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf
- Nilotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf
- Dasatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf
- Ponatinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf
- Bosutinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/20334s007s008lbl.pdf
- Seshadri T, Seymour JF, McArthur GA, et al., Oligospermia in patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351(20):2134–2135.
- Mariani S, Basciani S, Fabbri A, et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril. 2011 Mar 1;95(3):1120.e15-7.
- Xiaohui CL, Lin Z, Xiaoxia C, et al., Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase. Targ Oncol. 2017;12(6):827–832.
- Christopoulus C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 2008;358(10):1079–1080.
- Alberuni MZ, Michael JM, Brian JD, et al. Will imatinib compromise reproductive capacity? Oncologist. 2011;16(10):1422–1427.
- Abruzzese E, Mauro M, Apperley J, et al. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol. 2020 Oct 31;11:2040620720966120.
- Chelysheva E, Turkina A, Polushkina E, et al. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. Leuk Lymphoma. 2018;59(3):733–738.
- Pye SM, Cortes J, Ault P, et al., The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–5508.
- National Toxicology Program. NTP Monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. NTP Monogr. 2013;(2):i–214.
- Shash E, Bassi S, Cocorocchio E, et al. Fatherhood during imatinib. Acta Oncol. 2011;50(5):734–735.
- Abruzzese E, Trawinska MM, Perrotti AP, et al., Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6(1): e2014028.
- Cortes JE, Abruzzese E, Chelysheva E, et al., The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111–1115.
- Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380(6573):435–439.
- Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 2005;6(2):209.
- Jojovic M, Wolf F, Mangold U. Epidermal growth factor, vascular endothelial growth factor and progesterone promote placental development in rat whole-embryo culture. Anat Embryol (Berl.). 1998;198(2):133–139.
- Dantzer V, Winther H. Histological and immunohistochemical events during placentation in pigs. Reprod Suppl. 2001;58:209–222.
- Demir R, Kayisli UA, Seval Y, et al. Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis. Placenta. 2004;25(6):560–572.
- Pauli SA, Tang H, Wang J, et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology. 2005;146(3):1301–1311. .
- Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15–35. (discussion 35–16).
- Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380(6573):439–442.
- Sunitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf
- Sorafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdf
- Pazopanib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf
- Bevacizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf
- Coburn AM, Cappon GD, Bowman C, et al. Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats. Birth Defects Res B Dev. Reprod Toxicol.. 2012;95(4):267–275.
- Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer. 2010 Aug 16;17(3):R233–44.
- De Sanctis R, Lorenzi E, Elisa A, et al., Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient A CARE-compliant case report. Medicine (Baltimore). 2019;98(50): e18089.
- Allegra CJ, Yothers G, O’Connell MJ, et al., Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27(20):3385–3390.
- Mahdi AJ, Gosrani D, Chakraborty M, et al., Successful molecular targeted treatment of AML in pregnancy with azacitidine and sorafenib with no adverse fetal outcomes. Br J Haematol. 2018;180(4):578–606.
- Tarantola RM, Folk JC, Boldt HC, et al. Intravitreal bevacizumab during pregnancy. Retina. 2010;30(9):1405–1411.
- Schneider MR, Wolf E. The epidermal growth factor receptor and its ligands in female reproduction: insights from rodent models. Cytokine Growth Factor Rev. 2008;19(2):173–181.
- Evaul K, Hammes SR. Cross-talk between G protein-coupled and epidermal growth factor receptors regulates gonadotropin-mediated steroidogenesis in Leydig cells. J Biol Chem. 2008;283(41):27525–27533.
- Erlotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
- Gefitinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf
- Osimertinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf
- Nishio M, Ohyanagi F, Horiike A, et al., Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. Br J Cancer. 2005;92(10): 1877–1880.
- Jovelet C, Seck A, Mir O, et al. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Ann Oncol. 2015;26(7):1500–1504.
- Gil S, Goetghelucka J, Pacie A, et al., Efficacy and safety of gefitinib during pregnancy: case report and literature review. Lung Cancer. 2014;85(3):481–484.
- Yongli J, Schwartz J, Hartford A, et al., Successful treatment of non–small cell lung cancer with erlotinib throughout pregnancy. JAMA Oncol. 2015;1(6): 838–840.
- Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634–1657.
- Smyth EC, Verheij M, Allum W, et al. ESMO guidelines committee. gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49.
- Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–2516.
- Grégoire V, Lefebvre JL, Licitra L, et al. EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184–6.
- T-DM1: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf
- Trastuzumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf
- Panitumumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdf
- Lambertini M, Campbell C, Bines J, et al. Adjuvant Anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2019;111(1):86–94.
- Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791–798.
- Ruddy KJ, Guo H, Barry W, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151(3):589–596.
- Pertuzumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125409s051lbl.pdf
- Cetuximab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
- Calsteren KV, Verbesselt R, Devlieger R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer. 2010;20(9):1456–1464.
- Boix-Perales H, Borregaard J, Jensen KB, et al. The European Medicines Agency review of pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2014;19(7):766–773.
- Miyamoto S, Yamada M, Kasai Y, et al. Anticancer drugs during pregnancy. Jpn J Clin Oncol. 2016 Sep;46(9):795–804. . Epub 2016 Jun 9. PMID: 27284093.
- Lambertini M, Martel S, Campbell C, et al., Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: analysis from the NeoALTTO (BIG 1–06) and ALTTO (BIG 2–06) trials. Cancer. 2019;125(2): 307–316.
- Zagouri F, Sergentanis TN, Chrysikos D, et al., Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(2):349–357.
- Azim HA, Peccatori FA, Pavlidis N, et al., Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev. 2010;36(2):101–109.
- A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine (MotHER). https://clinicaltrials.gov/ct2/show/NCT00833963
- Colombo N, Sessa C, Du Bois A, et al. ESMO-ESGO ovarian cancer consensus conference working group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672–705.
- Olaparib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf
- Qian H, Xu J, Lalioti MD, et al. Oocyte numbers in the mouse increase after treatment with 5-aminoisoquinolinone: a potent inhibitor of poly(ADP-ribosyl)ation. Biol Reprod. 2010;82(5):1000–1007.
- Winship AL, Griffiths M, Lliberos Requesens C, et al. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. Hum Reprod. 2020 Aug 1;35(8):1864–1874.
- Turan V, Oktay K. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. Hum Reprod Update. 2020;26(1):43–57.
- Oktay KH, Bedoschi G, Goldfarb SB, et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril. 2020 Jun;113(6):1251–1260.
- Celik-Ozenci C, Tasatargil A. Role of poly(ADP-ribose) polymerases in male reproduction. Spermatogenesis. 2013;3(2):e24194.
- Crizotinib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf
- Elliot J, Bai Z, Hsieh SC, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PLoS One. 2020;15(2):e0229179.
- Witek B, El Wakil A, Nord C, et al. Targeted disruption of ALK reveals a potential role in hypogonadotropic hypogonadism. PLoS One. 2015;10(5):e0123542.
- Weickhardt AJ, Rothman MS, Salian-Mehta S. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012;118(21):5302–5309.
- Weickhardt AJ, Doebele RC, Purcell WT, et al. Reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013;119(13):2383–2390.
- Eliesen GAM, van den Broek P, van den Heuvel JJ, et al. Editor’s highlight: placentaldisposition and effects of crizotinib: an Ex vivo study in the isolated dual-side perfused human cotyledon. Toxicol Sci. 2017;157(2):500–509.
- Neves I, Mota PC, Hespanhol VP. Lung cancer during pregnancy: an unusual case. Rev Port Pneumol. 2014 Jan-Feb;20(1):46–49; English, Portuguese. Epub 2013 Jul 31. PMID: 23910397.
- Curtin JA, Fridly J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–2147.
- Wu PK, Becker A, Park JI. Growth inhibitory signaling of the Raf/MEK/ERK pathway. Int J Mol Sci. 2020;21(15):5436.
- Vemurafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdf
- Dabrafenib: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf
- Ghezzi M, Garolla A, Magagna S, et al. Fertility outcomes and sperm-DNA parameters in metastatic melanoma survivors receiving vemurafenib or dabrafenib therapy: case report. Front Oncol. 2020;10:232.
- Cocorocchio E, Pala L, Battaglia A, et al. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. Acta Oncol. 2018;57(8):1131–1133.
- Maleka A, Enblad G, Sjörs G, et al. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol. 2013;31(11):e192–3.
- de Haan J, van Thienen JV, Casaer M, et al. Severe adverse reaction to vemurafenib in a pregnant woman with metastatic melanoma. Case Rep Oncol. 2018;11(1):119–124.
- Lambertini M, Demeestere I, Viglietti G, et al., Oncofertility counselling in premenopausal women with HER2-positive breast cancer. Oncotarget. 2019;10(9): 926–929.
- Loren AW, Mangu PB, Beck LN, et al., American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19): 2500–2510.
- Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015 Nov;1(8):1145–1153. 1(8):1172.
- Peccatori FA, Azim HA, Orecchia R, et al. ESMO guidelines working group cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;246:vi160–70
- Lambertini M, Peccatori FA, Azim HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015;41(4):301–309.